Gut microbiota and metabolites in α-synuclein transgenic monkey models of early stage Parkinson’s disease

Parkinson’s disease has become the second most serious neurodegenerative disease, including complex non-motor symptoms and movement disorders. Anxiety and cognitive impairment are typical early Parkinson's symptoms. Normal individuals and Parkinson's patients has exist difference in gut microbiota and same metabolites. But it is unclear whether gut bacteria and metabolites play a role in early Parkinson's disease. In the previous study we successfully constructed transgenic monkeys with early Parkinson's symptoms. Now we have analyzed the gut microbiota and metabolites of these monkeys. Compared with the wild monkeys, we found that there were differences in intestinal microbiota and metabolites in monkeys with early Parkinson's symptoms. Eggerthella lenta is significantly elevated in PD patients and A53T in transgenic monkeys. We filtered five differential metabolites, three of these metabolites have been reported to be associated with neurological disease or brain development, but have not been found in Parkinson so far. We also found that the gut microbiota and pathways associated with these five differential metabolites, four KOs may play a role in Parkinson's disease. Our study first described the association of intestinal bacteria, metabolites, and early Parkinson's disease. Our study also provides a reference for early screening and diagnosis of early Parkinson's disease.